文献速递湿疹皮炎与荨麻疹

巴瑞替尼对比硫唑嘌呤联合外用糖皮质激素治疗中重度特应性皮炎

Efficacy and safety of baricitinib versus azathioprine, both combined with topical corticosteroids, in patients with moderate-to-severe atopic dermatitis: a single-centre randomized open-label trial.
PubMed 文献 · Br J Dermatol · 2026-01-01

这项单中心开放标签随机头对头试验纳入40例中重度特应性皮炎成人患者,比较巴瑞替尼(4 mg/日)与硫唑嘌呤(1.5–2.5 mg/kg/日)联合外用糖皮质激素治疗12周的疗效与安全性。结果显示巴瑞替尼组EASI 75应答率显著高于硫唑嘌呤组(65% vs 15%,P=0.002),两组均耐受良好,无严重不良事件或因不良事件停药。

要点

  • 巴瑞替尼联合TCS治疗12周EASI 75应答率65%,显著高于硫唑嘌呤联合TCS的15%。
  • 巴瑞替尼组SCORAD 75应答率55%,亦显著高于硫唑嘌呤组的15%。
  • 两组均耐受良好,未记录严重不良事件或停药。

核心结论

  • 在中重度特应性皮炎成人患者中,巴瑞替尼联合外用糖皮质激素治疗12周的疗效优于硫唑嘌呤联合外用糖皮质激素,且两者安全性均良好。

研究设计与样本

  • 单中心、开放标签、随机头对头试验(NCT05969730),40例中重度特应性皮炎成人患者按1:1随机分配至巴瑞替尼(4 mg/日)或硫唑嘌呤(1.5–2.5 mg/kg/日)组,均联合外用糖皮质激素及10%尿素乳膏治疗12周。

主要发现

  • 第12周时,巴瑞替尼+TCS组65%(13/20)达到EASI 75,硫唑嘌呤+TCS组为15%(3/20),差异50%(95%CI 23.9–76.1;P=0.002)。
  • 基线校正后治疗后平均EASI评分(SD)巴瑞替尼组为5.60(7.51),硫唑嘌呤组为12.61(7.51),差异-7.01(95%CI -11.86至-2.17;P=0.006),效应量大(Cohen's d=-0.93)。
  • SCORAD 75应答率巴瑞替尼+TCS组为55%(11/20),硫唑嘌呤组为15%(3/20),差异40%(95%CI 13.2–66.8;P=0.01)。
  • 两组的vIGA-AD、瘙痒NRS、皮肤疼痛NRS、POEM、DLQI及HADS评分均有改善,趋势 favoring 巴瑞替尼,但组间差异无统计学意义。
  • 两种治疗均耐受良好,无严重不良事件或停药记录。

关键数值与推荐

  • 主要终点为第12周达到EASI 75的患者比例,巴瑞替尼+TCS组为65%(13/20),硫唑嘌呤+TCS组为15%(3/20),差异50%(95%CI 23.9–76.1;P=0.002)。
  • 次要终点SCORAD 75应答率巴瑞替尼+TCS组为55%(11/20),硫唑嘌呤组为15%(3/20),差异40%(95%CI 13.2–66.8;P=0.01)。

临床怎么用

  • 对于中重度特应性皮炎成人患者,巴瑞替尼联合外用糖皮质激素可作为优于硫唑嘌呤联合外用糖皮质激素的短期系统治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can be difficult to manage in moderate-to-severe cases. Baricitinib (a Janus kinase 1/2 inhibitor) and azathioprine (a traditional immunosuppressant) are both used in the systemic treatment of AD. OBJECTIVES: To compare the efficacy and safety of baricitinib vs. azathioprine, both combined with topical corticosteroids (TCS), in adults with moderate-to-severe AD. METHODS: In this single-centre open-label randomized head-to-head trial (NCT05969730), 40 adults with moderate-to-severe AD were randomly assigned 1 : 1 to receive baricitinib (4 mg daily) or azathioprine (1.52.5 mg kg-1 daily), both with TCS and urea 10% cream, for 12 weeks. The primary endpoint was the proportion of patients achieving ≥ 75% reduction in Eczema Area and Severity Index (EASI 75) at week 12. RESULTS: At week 12, 65% (n = 13/20) of patients in the baricitinib + TCS group achieved EASI 75 vs. 15% (n = 3/20) in the azathioprine + TCS group [difference 50%, 95% confidence interval (CI) 23.9-76.1; P = 0.002]. The baseline-adjusted post-treatment mean (SD) EASI scores were 5.60 (7.51) for baricitinib and 12.61 (7.51) for azathioprine (difference -7.01, 95% CI -11.86 to -2.17; P = 0.006), with a large effect size (Cohen's d = -0.93). A ≥ 75% decrease in SCORing Atopic Dermatitis score (SCORAD 75) was achieved by 55% (n = 11/20) in the baricitinib + TCS group vs. 15% (n = 3/20) in the azathioprine group (difference 40%, 95% CI 13.2-66.8; P = 0.01). Improvements in validated Investigator's Global Assessment for AD, Itch Numeric Rating Scale (NRS), Skin Pain NRS, Patient-Oriented Eczema Measure, Dermatology Life Quality Index and Hospital Anxiety and Depression Scale scores were found in both groups, with a trend favouring baricitinib, although the differences between groups were not statistically significant. Both treatments were well tolerated, with no serious adverse events or discontinuations recorded. CONCLUSIONS: Baricitinib + TCS demonstrated superior efficacy to azathioprine + TCS in adults with moderate-to-severe AD, both with a well-tolerated safety profile at 12 weeks. Atopic dermatitis (also called eczema) is a long-term skin condition. It causes dry, itchy and inflamed skin. Treatment with specific skin creams is common. Some adults need to take other medication to manage their symptoms. In this clinical trial, we compared two medicines used to treat eczema. The trial included 40 adults with moderate-to-severe eczema. One of the medicines was ‘baricitinib’. This medication blocks signals in the immune system that cause inflammation. The other medicine tested was ‘azathioprine’. It is an older medicine that reduces immune activity more generally. All participants also used a type of skin cream called ‘topical corticosteroids’. The participants were divided into two groups. The first group received baricitinib and the second group received azathioprine. Participants took the medications for 12 weeks. Doctors checked for improvements in eczema. They also recorded any side effects. Patients who took baricitinib had more of an improvement than those taking azathioprine. Both medicines were generally safe. No serious side effects resulted in anyone stopping treatment. When used along with skin creams, baricitinib can ease eczema symptoms more effectively in adults than azathioprine.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Malekan M, Rahmatpour Rokni G, Gholizadeh N, et al. Efficacy and safety of baricitinib versus azathioprine, both combined with topical corticosteroids, in patients with moderate-to-severe atopic dermatitis: a single-centre randomized open-label trial. Br J Dermatol. 2026. PMID: 41239194. doi:10.1093/bjd/ljaf456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。